Jul 1, 2006 Issue
Antihypertensive Agents for Prevention of Diabetic Nephropathy [Cochrane for Clinicians]

Angiotensin-converting enzyme (ACE) inhibitors are the only antihypertensive agents with proven effectiveness for the primary prevention of diabetic nephropathy (defined as an albumin excretion of less than 30 mg per day on three serial measurements) caused by type 1 or type 2 diabetes. However, ACE...

Jun 15, 2006 Issue
Few Americans with Diabetes Receive Multiple Preventive-Care Services [Practice Guidelines]

Preventive-care services such as annual foot and dilated eye examinations and biannual A1C tests can prevent or delay amputation and blindness from diabetes. The Centers for Disease Control and Prevention (CDC) analyzed data from the Behavioral Risk Factor Surveillance System surveys to determine th...

Jun 15, 2006 Issue
Exenatide Injection (Byetta): Adjunctive Therapy for Glycemic Control [STEPS]

Exenatide is an injectable treatment for type 2 diabetes. Its use requires patient education and strict monitoring of glucose levels because of the difficulty of its administration; therefore, it may not be a safe or practical option for patients who are not willing or able to administer exenatide correctly.

Feb 15, 2006 Issue
Preventing CVD in Patients with Type 1 Diabetes [Practice Guidelines]

A report that identifies ways to improve prevention and treatment of cardiovascular disease (CVD) in persons with type 1 diabetes has been released by the National Heart, Lung, and Blood Institute (NHLBI) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

Feb 1, 2006 Issue
Are Alpha-glucosidase Inhibitors Effective for Control of Type 2 Diabetes? [Cochrane for Clinicians]

The use of alpha-glucosidase inhibitors has a modest effect on intermediate diabetes-control endpoints such as postprandial blood glucose, postprandial insulin levels, and A1C levels. There is no evidence, however, of improvement in mortality, morbidity, or quality of life. In comparisons with sulfo...

Dec 1, 2005 Issue
Diabetic Nephropathy [Clinical Evidence Handbook]

What are the effects of treatments in persons with type 1 diabetes and early or late nephropathy? What are the effects of treatments in persons with type 2 diabetes and early or late nephropathy?

Oct 1, 2005 Issue
AAP Clinical Report on Diabetic Retinopathy [Practice Guidelines]

A clinical report reviewing the risk factors and screening guidelines for diabetic retinopathy in children has been released by the American Academy of Pediatrics (AAP), in conjunction with the American Association for Pediatric Ophthalmology and Strabismus (AAPOS).

Sep 1, 2005 Issue
Short-Acting Insulin Analogues vs. Human Insulin for Diabetes [Cochrane for Clinicians]

For patients with type 2 diabetes, regular insulin and short-acting insulin analogues are equally effective in the treatment of diabetes and in lowering A1C levels. For patients with type 1 diabetes, short-acting analogues produce a slightly greater reduction of A1C levels than regular insulin. Regu...

Jul 1, 2005 Issue
Diabetic Nephropathy: Common Questions [Article]

Diabetic nephropathy, or diabetic kidney disease, affects 20 to 30 percent of patients with diabetes. It is a common cause of kidney failure. Diabetic nephropathy presents in its earliest stage with low levels of albumin (microalbuminuria) in the urine. The most practical method of screening for mic...

Jun 1, 2005 Issue
Evaluation and Prevention of Diabetic Neuropathy [Article]

Diabetic neuropathy is a debilitating disorder that occurs in nearly 50 percent of patients with diabetes. It is a late finding in type 1 diabetes but can be an early finding in type 2 diabetes. The primary types of diabetic neuropathy are sensorimotor and autonomic. Patients may present with only o...

Pages: Previous 1 ... 8 9 10 11 12 13 14 15 16 17 Next

Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now